2026/01/22

CIC bioGUNE’s Genome Analysis Platform recognized as Certified NGS Service Provider by Revvity and Parse Biosciences

CIC bioGUNE’s Genome Analysis Platform (GAP) has been formally recognised as a certified and recommended Next-Generation Sequencing (NGS) service laboratory by Revvity and Parse Biosciences, two leading international companies in genomics technologies. This recognition represents an important milestone for the centre and highlights the platform’s technical excellence and commitment to high-quality genomics services.

CIC bioGUNE, member of BRTA, is now included in the Revvity NGS Certified Lab Program, a global network of laboratories that meet rigorous quality and performance standards in the application of NGS technologies. Through this certification, Revvity acknowledges CIC bioGUNE as a trusted provider of NGS services, reinforcing confidence among academic and industrial users in the reliability and reproducibility of the data generated. The certification is publicly available on Revvity’s website: https://www.revvity.com/revvity-ngs-certified-labs

In addition, the Genome Analysis Platform has been listed as a recommended service provider by Parse Biosciences, a company internationally recognised for its advanced single-cell and combinatorial indexing solutions. This inclusion reflects GAP’s proven expertise in the implementation of innovative genomics workflows and its ability to support complex, high-throughput experimental approaches: https://www.parsebiosciences.com/service-providers/

The Genome Analysis Platform, CIBERehd, is one of CIC bioGUNE’s core technology platforms, providing integrated genomics services that encompass experimental design, sample processing, library preparation, high-throughput sequencing and advanced bioinformatics analysis. The platform supports both internal research programmes and external academic, clinical and industrial collaborations, contributing decisively to the centre’s research excellence in areas such as cancer biology, rare diseases and molecular medicine.

This dual recognition by Revvity and Parse Biosciences further reinforces CIC bioGUNE’s position as a reference centre in genomics and advanced molecular technologies and underlines the strategic importance of its platforms in supporting high-quality, internationally competitive biomedical research.

About CIC bioGUNE

The Centre for Cooperative Research in Biosciences (CIC bioGUNE), member of the Basque Research & Technology Alliance (BRTA), located in the Bizkaia Technology Park, is a biomedical research organisation conducting cutting-edge research at the interface between structural, molecular and cell biology, with a particular focus on generating knowledge on the molecular bases of disease, for use in the development of new diagnostic methods and advanced therapies.

About BRTA

BRTA is an alliance of 4 collaborative research centres (CIC bioGUNE, CIC nanoGUNE, CIC biomaGUNE y CIC energiGUNE) and 13 technology centres (Azterlan, Azti, Ceit, Cidetec, Gaiker, Ideko, Ikerlan, Leartiker, Lortek, Neiker, Tecnalia, Tekniker y Vicomtech) with the main objective of developing advanced technological solutions for the Basque corporate fabric.

With the support of the Basque Government, the SPRI Group and the Provincial Councils of the three territories, the alliance seeks to promote collaboration between the research centres, strengthen the conditions to generate and transfer knowledge to companies, contributing to their competitiveness and outspreading the Basque scientific-technological capacity abroad.

BRTA has a workforce of 3,500 professionals, executes 22 % of the Basque Country's R&D investment, registers an annual turnover of more than 300 million euros and generates 100 European and international patents per year.

Spanish version